S tructural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody
Abstract
Abstract Recent studies have implicated a role of the epidermal growth factor receptor (EGFR) pathway in kidney disease. Skin toxicity associated with therapeutics which completely block the EGFR pathway precludes their use in chronic dosing. Therefore, we developed antibodies which specifically neutralize the EGFR ligands TGFα (transforming growth factor‐alpha) and epiregulin but not EGF (epidermal growth factor), amphiregulin, betacellulin, HB‐EGF (heparin‐binding epidermal growth factor), or epigen. The epitope of one such neutralizing antibody, LY3016859, was characterized in detail to elucidate the structural basis for ligand specificity. Here we report a crystal structure of the LY3016859 Fab fragment in complex with soluble human TGFα. Our data demonstrate a conformational epitope located primarily within the C‐terminal subdomain of the ligand. In addition, point mutagenesis experiments were used to highlight specific amino acids which are critical for both antigen binding and neutralization, most notably Ala 41 , Glu 44 , and His 45 . These results illustrate the structural basis for the ligand specificity/selectivity of LY3016859 and could also provide insight into further engineering to alter specificity and/or affinity of LY3016859.
- Authors:
-
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana 46285
- Eli Lilly Biotechnology Center San Diego California 92121
- Publication Date:
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 1401704
- Grant/Contract Number:
- DE‐AC02‐06CH11357
- Resource Type:
- Publisher's Accepted Manuscript
- Journal Name:
- Protein Science
- Additional Journal Information:
- Journal Name: Protein Science Journal Volume: 25 Journal Issue: 11; Journal ID: ISSN 0961-8368
- Publisher:
- Wiley Blackwell (John Wiley & Sons)
- Country of Publication:
- United Kingdom
- Language:
- English
Citation Formats
Boyles, Jeffrey S., Atwell, Shane, Druzina, Zhanna, Heuer, Josef G., and Witcher, Derrick R. S tructural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody. United Kingdom: N. p., 2016.
Web. doi:10.1002/pro.3023.
Boyles, Jeffrey S., Atwell, Shane, Druzina, Zhanna, Heuer, Josef G., & Witcher, Derrick R. S tructural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody. United Kingdom. https://doi.org/10.1002/pro.3023
Boyles, Jeffrey S., Atwell, Shane, Druzina, Zhanna, Heuer, Josef G., and Witcher, Derrick R. Fri .
"S tructural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody". United Kingdom. https://doi.org/10.1002/pro.3023.
@article{osti_1401704,
title = {S tructural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody},
author = {Boyles, Jeffrey S. and Atwell, Shane and Druzina, Zhanna and Heuer, Josef G. and Witcher, Derrick R.},
abstractNote = {Abstract Recent studies have implicated a role of the epidermal growth factor receptor (EGFR) pathway in kidney disease. Skin toxicity associated with therapeutics which completely block the EGFR pathway precludes their use in chronic dosing. Therefore, we developed antibodies which specifically neutralize the EGFR ligands TGFα (transforming growth factor‐alpha) and epiregulin but not EGF (epidermal growth factor), amphiregulin, betacellulin, HB‐EGF (heparin‐binding epidermal growth factor), or epigen. The epitope of one such neutralizing antibody, LY3016859, was characterized in detail to elucidate the structural basis for ligand specificity. Here we report a crystal structure of the LY3016859 Fab fragment in complex with soluble human TGFα. Our data demonstrate a conformational epitope located primarily within the C‐terminal subdomain of the ligand. In addition, point mutagenesis experiments were used to highlight specific amino acids which are critical for both antigen binding and neutralization, most notably Ala 41 , Glu 44 , and His 45 . These results illustrate the structural basis for the ligand specificity/selectivity of LY3016859 and could also provide insight into further engineering to alter specificity and/or affinity of LY3016859.},
doi = {10.1002/pro.3023},
journal = {Protein Science},
number = 11,
volume = 25,
place = {United Kingdom},
year = {Fri Sep 09 00:00:00 EDT 2016},
month = {Fri Sep 09 00:00:00 EDT 2016}
}
https://doi.org/10.1002/pro.3023
Web of Science
Works referenced in this record:
Shape Complementarity at Protein/Protein Interfaces
journal, December 1993
- Lawrence, Michael C.; Colman, Peter M.
- Journal of Molecular Biology, Vol. 234, Issue 4
Overview of the CCP 4 suite and current developments
journal, March 2011
- Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.
- Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4
Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α
journal, September 2002
- Garrett, Thomas P. J.; McKern, Neil M.; Lou, Meizhen
- Cell, Vol. 110, Issue 6
Epidermal growth factor receptor targeting in cancer: A review of trends and strategies
journal, November 2013
- Yewale, Chetan; Baradia, Dipesh; Vhora, Imran
- Biomaterials, Vol. 34, Issue 34
Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor
journal, September 2002
- Schlessinger, Joseph
- Cell, Vol. 110, Issue 6
MolProbity : all-atom structure validation for macromolecular crystallography
journal, December 2009
- Chen, Vincent B.; Arendall, W. Bryan; Headd, Jeffrey J.
- Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 1
Coot model-building tools for molecular graphics
journal, November 2004
- Emsley, Paul; Cowtan, Kevin
- Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 12, p. 2126-2132
A transcriptional network underlies susceptibility to kidney disease progression
journal, June 2012
- Laouari, Denise; Burtin, Martine; Phelep, Aurélie
- EMBO Molecular Medicine, Vol. 4, Issue 8
Genetic or Pharmacologic Blockade of EGFR Inhibits Renal Fibrosis
journal, February 2012
- Liu, Na; Guo, Jian-Kan; Pang, Maoyin
- Journal of the American Society of Nephrology, Vol. 23, Issue 5
REFMAC 5 dictionary: organization of prior chemical knowledge and guidelines for its use
journal, November 2004
- Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.
- Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 12
Identification of heavy-atom derivatives by normal probability methods
journal, February 1992
- Howell, P. L.; Smith, G. D.
- Journal of Applied Crystallography, Vol. 25, Issue 1
Regulation of Cell Proliferation by Epidermal Growth Factor
journal, January 1983
- Schlessinger, Joseph; Schreiber, Alain B.; Levi, Andrea
- Critical Reviews in Biochemistry, Vol. 14, Issue 2
Generation and Activity of a Humanized Monoclonal Antibody That Selectively Neutralizes the Epidermal Growth Factor Receptor Ligands Transforming Growth Factor- α and Epiregulin
journal, February 2014
- Beidler, Catherine B.; Petrovan, Ramona J.; Conner, Elaine M.
- Journal of Pharmacology and Experimental Therapeutics, Vol. 349, Issue 2
On the treatment of negative intensity observations
journal, July 1978
- French, S.; Wilson, K.
- Acta Crystallographica Section A, Vol. 34, Issue 4
The biochemistry and physiology of the receptor-kinase for epidermal growth factor
journal, July 1983
- Carpenter, Graham
- Molecular and Cellular Endocrinology, Vol. 31, Issue 1
Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions
journal, November 2004
- Krissinel, E.; Henrick, K.
- Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 12
The Significance of Valine 33 as a Ligand-specific Epitope of Transforming Growth Factor α
journal, June 1996
- Puddicombe, Sarah M.; Chamberlin, Stephen G.; MacGarvie, Jennie
- Journal of Biological Chemistry, Vol. 271, Issue 26
The EGFR family and its ligands in human cancer
journal, September 2001
- Yarden, Y.
- European Journal of Cancer, Vol. 37
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach
journal, July 2005
- Lautrette, Alexandre; Li, Shunqiang; Alili, Rohia
- Nature Medicine, Vol. 11, Issue 8
TGF-α Mediates Genetic Susceptibility to Chronic Kidney Disease
journal, December 2010
- Laouari, Denise; Burtin, Martine; Phelep, Aurélie
- Journal of the American Society of Nephrology, Vol. 22, Issue 2
Angiotensin II receptor blockade in diabetic nephropathy
journal, January 2003
- Lewis, E.
- American Journal of Hypertension, Vol. 16, Issue 1
Cutaneous side-effects of kinase inhibitors and blocking antibodies
journal, July 2005
- Robert, Caroline; Soria, Jean-Charles; Spatz, Alain
- The Lancet Oncology, Vol. 6, Issue 7
Skin toxicities associated with epidermal growth factor receptor inhibitors
journal, May 2009
- Li, Tianhong; Perez-Soler, Roman
- Targeted Oncology, Vol. 4, Issue 2
Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury
journal, July 2000
- Terzi, Fabiola; Burtin, Martine; Hekmati, Mehrak
- Journal of Clinical Investigation, Vol. 106, Issue 2
Phaser crystallographic software
journal, July 2007
- McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.
- Journal of Applied Crystallography, Vol. 40, Issue 4